Loading
No description yet: the sentence for this tag has not been written. 14 records carry it: 13 drugs, 1 target.
| Cancers | Other tags | ||||
|---|---|---|---|---|---|
BBI-355 BBI-355 BBI-355 is an oral small-molecule inhibitor from Boundless Bio that reached phase 1 for solid tumours with oncogene amplifications; development has stopped. | Phase 1 | Metastatic cancer | none | pipeline | |
BBI-825 BBI-825 BBI-825 is an oral small-molecule inhibitor from Boundless Bio that reached phase 1 for solid tumours with resistance gene amplifications; development has stopped. | Phase 1 | Metastatic cancer | none | pipeline | |
BBI-940 BBI-940 BBI-940 is an oral small-molecule degrader from Boundless Bio that reached phase 1 for ER-positive/HER2-negative breast cancer and luminal androgen receptor triple-negative breast cancer; development has stopped. | Phase 1 | HR-positive / HER2-negative breast cancer, Triple-negative breast cancer | none | pipeline | |
BPX-603 BPX-603 BPX-603 is an autologous dual-switch CAR-T cell therapy from Bellicum Pharmaceuticals that reached phase 1 for HER2-positive solid tumours, HER2-positive gastric cancer and HER2-positive breast cancer; development has stopped. | Phase 1 | Metastatic cancer, HER2-positive gastric cancer, HER2-positive breast cancer | none | pipeline | |
FHD-909 FHD-909 FHD-909 is an oral small-molecule allosteric inhibitor from Foghorn Therapeutics that reached phase 1 for SMARCA4-mutant non-small cell lung cancer and SMARCA4-deficient solid tumours; development has stopped. | Phase 1 | Metastatic cancer | none | pipeline | |
Firicabtagene autoleucel CRG-022 Firicabtagene autoleucel is an autologous CAR T-cell therapy from CARGO Therapeutics that reached phase 2 for relapsed or refractory large B-cell lymphoma; development has stopped. | Phase 2 | Non-Hodgkin lymphoma | none | pipeline | |
ITIL-168 ITIL-168 ITIL-168 is an autologous tumour-infiltrating lymphocyte cell therapy from Instil Bio that reached phase 2 for advanced cutaneous melanoma, cervical cancer and head and neck squamous cell carcinoma and other cancers; development has stopped. | Phase 2 | Melanoma, Cervical cancer, Head and neck squamous cell carcinoma | none | pipeline | |
ITIL-306 ITIL-306 ITIL-306 is an autologous tumour-infiltrating lymphocyte cell therapy with a co-stimulatory antigen receptor from Instil Bio that reached phase 1 for epithelial ovarian cancer, non-small cell lung cancer and renal cell carcinoma; development has stopped. | Phase 1 | Ovarian cancer, Non-small-cell lung cancer, Renal cell carcinoma | none | pipeline | |
LIV-1 (SLC39A6) SLC39A6 LIV-1 is an oestrogen-regulated zinc transporter on most breast cancers; the ADC against it (ladiratuzumab vedotin) showed activity in triple-negative disease but was discontinued in 2024. | Triple-negative breast cancer, HR-positive / HER2-negative breast cancer, Prostate cancer | none | none | ||
ORM-5029 ORM-5029 ORM-5029 is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for HER2-expressing advanced solid tumours, including HER2-positive breast cancer; development has stopped. | Phase 1 | HER2-positive breast cancer | none | pipeline | |
ORM-6151 (BMS-986497) ORM-6151 ORM-6151 (BMS-986497) is a degrader-antibody conjugate from Orum Therapeutics that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped. | Phase 1 | Acute myeloid leukaemia, Myelodysplastic syndromes / neoplasms | none | pipeline | |
Rivogenlecleucel BPX-501 Rivogenlecleucel is an allogeneic polyclonal T cell therapy with an inducible caspase-9 safety switch from Bellicum Pharmaceuticals that reached phase 3 for acute myeloid leukaemia, acute lymphoblastic leukaemia and myelodysplastic syndromes and other cancers; development has stopped. | Phase 3 | Acute myeloid leukaemia, Acute lymphoblastic leukaemia, Myelodysplastic syndromes / neoplasms | none | pipeline | |
Rocapuldencel-T AGS-003 Rocapuldencel-T is an individualised autologous dendritic cell immunotherapy from Argos Therapeutics that reached phase 3 for metastatic renal cell carcinoma; development has stopped. | Phase 3 | Renal cell carcinoma | none | pipeline | |
SGR-2921 SGR-2921 SGR-2921 is a small molecule from Schrödinger that reached phase 1 for relapsed or refractory acute myeloid leukaemia and myelodysplastic syndrome; development has stopped. | Phase 1 | Acute myeloid leukaemia, Myelodysplastic syndromes / neoplasms | none | pipeline |